Yoichi Mashimo a, Keiko Yamazaki a, Takahiro Kageyama b, Shigeru Tanaka b, Toshibumi Taniguchi c, d, Kazuyuki Matsushita e, Hidetoshi Igari c, d, Hideki Hanaoka f, Koutaro Yokote g, Hiroshi Nakajima b, d, Yoshihiro Onouchi a, ⁎
a Department of Public Health, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
b Department of Allergy and Clinical Immunology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
c Department of Infectious Diseases, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
d Chiba University Hospital COVID-19 Vaccine Center, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
e Division of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
f Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan
g Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, Chiba 260-8670, Japan